Laplace Interventional is developing a Transcatheter tricuspid valve replacement (TTVR) system for patients with Tricuspid Regurgitation. This investigational device is designed to deliver a prosthetic valve percutaneously, avoiding open-heart surgery. The goal is to potentially improve the quality of life and increase life expectancy for affected patients.
Funding
$20.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCFounders
Product
Problem
Tricuspid regurgitation (TR) is a common heart valve disorder that can lead to significant complications and reduced quality of life. Current treatment options often involve open-heart surgery, which carries substantial risks and may not be suitable for all patients. There is a need for less invasive approaches to address TR and improve patient outcomes.
Solution
Laplace Interventional is developing a transcatheter tricuspid valve replacement (TTVR) system designed to treat tricuspid regurgitation through a minimally invasive procedure. The investigational prosthetic valve is delivered without the need for open-heart surgery, potentially reducing the risk of complications associated with traditional surgical approaches. The TTVR system aims to improve the life expectancy and quality of life for patients diagnosed with TR by restoring proper valve function and mitigating the adverse effects of regurgitation.
Target Audience
The primary target audience includes patients diagnosed with tricuspid regurgitation who are seeking a less invasive treatment option, as well as interventional cardiologists and cardiac surgeons specializing in heart valve disorders.
Features
- Minimally invasive delivery system for tricuspid valve replacement
- Designed to reduce complications associated with open-heart surgery
- Prosthetic valve intended to restore proper tricuspid valve function